Recent News

• 06.12.2025 - H.C. Wainwright “HCW@Home with vTv Therapeutics”
• 06.11.2025 - vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
• 06.11.2025 - vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
• 05.19.2025 - vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
• 05.19.2025 - vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
• 05.15.2025 - vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
• 05.15.2025 - vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
• 05.15.2025 - vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
• 05.15.2025 - vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Recent Filings

• 05.21.2025 - 3 Initial statement of beneficial ownership of securities
• 05.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 8-K Current report
• 05.19.2025 - EX-99.1 EX-99.1
• 05.16.2025 - 8-K Current report
• 05.16.2025 - EX-99.1 EX-99.1
• 05.15.2025 - 8-K Current report
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - EX-99.1 EX-99.1
• 05.01.2025 - 144 Report of proposed sale of securities